Biomarkers of DNA repair and related pathways: Significance in non-small cell lung cancer

Sacha I. Rothschild, Oliver Gautschi, Primo N Lara, Philip Mack, David R Gandara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose of review: To review selected biomarkers of DNA repair and related pathways as they relate to the management of patients with non-small cell lung cancer (NSCLC), emphasizing the role of individualized, chemotherapy for advanced disease, and discussing potential applications in early disease. Recent findings: The activity of molecular-targeted agents in NSCLC patients whose tumor possesses relevant biomarkers [such as epidermal growth factor receptor (EGFR) activating mutations and ALK translocations] has made personalized therapy possible. In addition, preclinical and clinical studies have shown that histopathological and biomolecular factors can correlate with clinical outcome in patients with NSCLC treated with chemotherapy. As a result, tumor histology is now routinely considered in selecting chemotherapy for NSCLC patients, such as pemetrexed for nonsquamous histology. Molecular tumor and host factors, including genes involved in DNA-repair and synthesis, are potentially even more relevant as predictive biomarkers of tumor response to chemotherapy. However, individual molecular markers and gene signatures need further validation and standardization, before routine use in the clinic can be recommended. Summary: In the era of molecular-targeted agents, individualized therapy based on molecular biomarkers has become a reality in the treatment of patients with advanced NSCLC. Further studies are needed to optimize current treatment algorithms with regard to biomarkers for chemotherapy benefit, to refine molecular markers, and to translate these findings to early stage NSCLC.

Original languageEnglish (US)
Pages (from-to)150-157
Number of pages8
JournalCurrent Opinion in Oncology
Volume23
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Non-Small Cell Lung Carcinoma
DNA Repair
Biomarkers
Drug Therapy
Pemetrexed
Histology
Neoplasms
Therapeutics
Tumor Biomarkers
Epidermal Growth Factor Receptor
Genes
Mutation

Keywords

  • biomarker
  • chemotherapy
  • gene expression
  • lung cancer
  • personalized medicine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Biomarkers of DNA repair and related pathways : Significance in non-small cell lung cancer. / Rothschild, Sacha I.; Gautschi, Oliver; Lara, Primo N; Mack, Philip; Gandara, David R.

In: Current Opinion in Oncology, Vol. 23, No. 2, 03.2011, p. 150-157.

Research output: Contribution to journalArticle

@article{fa6133a9cc034e29887da49466f4ae75,
title = "Biomarkers of DNA repair and related pathways: Significance in non-small cell lung cancer",
abstract = "Purpose of review: To review selected biomarkers of DNA repair and related pathways as they relate to the management of patients with non-small cell lung cancer (NSCLC), emphasizing the role of individualized, chemotherapy for advanced disease, and discussing potential applications in early disease. Recent findings: The activity of molecular-targeted agents in NSCLC patients whose tumor possesses relevant biomarkers [such as epidermal growth factor receptor (EGFR) activating mutations and ALK translocations] has made personalized therapy possible. In addition, preclinical and clinical studies have shown that histopathological and biomolecular factors can correlate with clinical outcome in patients with NSCLC treated with chemotherapy. As a result, tumor histology is now routinely considered in selecting chemotherapy for NSCLC patients, such as pemetrexed for nonsquamous histology. Molecular tumor and host factors, including genes involved in DNA-repair and synthesis, are potentially even more relevant as predictive biomarkers of tumor response to chemotherapy. However, individual molecular markers and gene signatures need further validation and standardization, before routine use in the clinic can be recommended. Summary: In the era of molecular-targeted agents, individualized therapy based on molecular biomarkers has become a reality in the treatment of patients with advanced NSCLC. Further studies are needed to optimize current treatment algorithms with regard to biomarkers for chemotherapy benefit, to refine molecular markers, and to translate these findings to early stage NSCLC.",
keywords = "biomarker, chemotherapy, gene expression, lung cancer, personalized medicine",
author = "Rothschild, {Sacha I.} and Oliver Gautschi and Lara, {Primo N} and Philip Mack and Gandara, {David R}",
year = "2011",
month = "3",
doi = "10.1097/CCO.0b013e328341ee38",
language = "English (US)",
volume = "23",
pages = "150--157",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Biomarkers of DNA repair and related pathways

T2 - Significance in non-small cell lung cancer

AU - Rothschild, Sacha I.

AU - Gautschi, Oliver

AU - Lara, Primo N

AU - Mack, Philip

AU - Gandara, David R

PY - 2011/3

Y1 - 2011/3

N2 - Purpose of review: To review selected biomarkers of DNA repair and related pathways as they relate to the management of patients with non-small cell lung cancer (NSCLC), emphasizing the role of individualized, chemotherapy for advanced disease, and discussing potential applications in early disease. Recent findings: The activity of molecular-targeted agents in NSCLC patients whose tumor possesses relevant biomarkers [such as epidermal growth factor receptor (EGFR) activating mutations and ALK translocations] has made personalized therapy possible. In addition, preclinical and clinical studies have shown that histopathological and biomolecular factors can correlate with clinical outcome in patients with NSCLC treated with chemotherapy. As a result, tumor histology is now routinely considered in selecting chemotherapy for NSCLC patients, such as pemetrexed for nonsquamous histology. Molecular tumor and host factors, including genes involved in DNA-repair and synthesis, are potentially even more relevant as predictive biomarkers of tumor response to chemotherapy. However, individual molecular markers and gene signatures need further validation and standardization, before routine use in the clinic can be recommended. Summary: In the era of molecular-targeted agents, individualized therapy based on molecular biomarkers has become a reality in the treatment of patients with advanced NSCLC. Further studies are needed to optimize current treatment algorithms with regard to biomarkers for chemotherapy benefit, to refine molecular markers, and to translate these findings to early stage NSCLC.

AB - Purpose of review: To review selected biomarkers of DNA repair and related pathways as they relate to the management of patients with non-small cell lung cancer (NSCLC), emphasizing the role of individualized, chemotherapy for advanced disease, and discussing potential applications in early disease. Recent findings: The activity of molecular-targeted agents in NSCLC patients whose tumor possesses relevant biomarkers [such as epidermal growth factor receptor (EGFR) activating mutations and ALK translocations] has made personalized therapy possible. In addition, preclinical and clinical studies have shown that histopathological and biomolecular factors can correlate with clinical outcome in patients with NSCLC treated with chemotherapy. As a result, tumor histology is now routinely considered in selecting chemotherapy for NSCLC patients, such as pemetrexed for nonsquamous histology. Molecular tumor and host factors, including genes involved in DNA-repair and synthesis, are potentially even more relevant as predictive biomarkers of tumor response to chemotherapy. However, individual molecular markers and gene signatures need further validation and standardization, before routine use in the clinic can be recommended. Summary: In the era of molecular-targeted agents, individualized therapy based on molecular biomarkers has become a reality in the treatment of patients with advanced NSCLC. Further studies are needed to optimize current treatment algorithms with regard to biomarkers for chemotherapy benefit, to refine molecular markers, and to translate these findings to early stage NSCLC.

KW - biomarker

KW - chemotherapy

KW - gene expression

KW - lung cancer

KW - personalized medicine

UR - http://www.scopus.com/inward/record.url?scp=79952006300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952006300&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328341ee38

DO - 10.1097/CCO.0b013e328341ee38

M3 - Article

C2 - 21119513

AN - SCOPUS:79952006300

VL - 23

SP - 150

EP - 157

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -